Global Intravenous Iron Drugs Market: Industry Analysis and Forecast (2021-2027) by Product Type, Applications, and Region

Global Intravenous Iron Drugs Market size was valued at US$ 2.4 Bn. in 2020 and the total revenue is expected to grow at 8.5% through 2021 to 2027, reaching nearly US$ 4.2 Bn.

Global Intravenous Iron Drugs Market Overview:

Iron, an essential metal, is involved in a variety of biological activities including heme synthesis, energy metabolism, neurotransmitter generation, myoglobin creation, collagen formation, and immune system activity. Iron deficiency is one of the leading causes of iron deficiency anemia (IDA), which is linked to an increased risk of morbidity and death. According to a 2017 investigation by the Vitamin and Mineral Nutrition Information System, iron deficiency leads to about 30% of anemia in women and children in poor nations. Pierre Blaud developed ferrous sulfate, which became the conventional therapy for IDA in the 19th century. Global Intravenous Iron Drugs MarketTo know about the Research Methodology :- Request Free Sample Report The report has covered the market trends from 2015 to forecast the market through 2027. 2020 Is considered a base year however 2020's numbers are on the real output of the companies in the market. Special attention is given to 2020 and the effect of lockdown on the demand and supply, and also the impact of lockdown for the next two years on the market. Some companies have done well in lockdown also and specific strategic analysis of those companies is done in the report.

Global Intravenous Iron Drugs Market Dynamics:

Iron Supplements are available in both the forms intravenous as well as oral form. Oral iron supplements are inferior to intravenous iron preparations, which result in a larger and faster increase in iron and hemoglobin levels. GI side effects, low adherence, poor gastrointestinal absorption, and non-compliance are among the drawbacks of oral supplements. The growth in the prevalence of iron deficiency, the rise in chronic renal disease patients undergoing dialysis, and the growing diabetes population are all major drivers of the IV iron medicines market. Demand for intravenous iron medicines is driven by an increase in iron deficiency anemia in gynecology, oncology, and gastroenterology, noncompliance with oral treatment, and accurate, quick, and reachable access to IV iron doses. However, the IV iron medicines market is anticipated to be constrained by a difficult approval procedure, rigorous regulations, medication side effects, nutraceutical options to avoid iron insufficiency, and product pricing. The COVID-19 Pandemic has hugely affected the manufacturing of pharmaceuticals due to lockdowns and no manpower around the globe. This factor further disrupted the supply chain. However, the market for intravenous iron medicines has grown due to strong attempts by manufacturers and the government to satisfy demand. Furthermore, some studies have linked COVID-19 infection to a higher risk of Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD), which has driven demand for intravenous iron medications to treat CKD-related anemia. As per the study carried out by National Kidney Foundation, People suffering from COVID-19 are more likely to suffer from Acute Kidney Injuries (AKI) in comparison to non-COVID patients. Further, the health authorities also recommended that COVID-19 patients who have suffered from acute kidney injuries (AKI) must go through regular testing for chronic kidney diseases (CKD). As the risk of chronic kidney disease (CKD) development is higher in COVID-19 patients as compared to others. Hence, these factors are likely to propel the growth of the market. One of the primary disadvantages of oral iron medications is the possibility of serious side effects. Stomach pains, constipation, lack of appetite, nausea, and vomiting are one of the most common side effects of oral iron treatments. Convulsions, short or fast breathing, lethargy or weakness, fatigue, pale skin, and bluish skin or fingernails all seem to be symptoms of an overdose of oral iron medications. Hence, these factors are estimated to hamper the growth of the market in the forecast period.

Global Intravenous Iron Drugs Market Segment Analysis:

The Ferric Carboxymaltose (FCM) segment is dominating the Product Type segment of the Global Intravenous Iron Drugs Market:

In 2020, the Ferric carboxymaltose (FCM) is likely to gain more attractions in the market due to growing applications, higher performance, and lower cost benefits with a revenue share of 46.9%. It's a dextran-free parenteral iron medication designed to replace depleted iron reserves quickly and at large doses. This medication is a stable compound with the advantages of not containing dextran and having a very low immunogenic potential, posing a very minimal risk of anaphylactic responses. Its advantageous features allow for a quick (15-minute) infusion without the need for a test dosage. As a result, the requirement for many tiny dosages and a long infusion duration is reduced. Ferric carboxymaltose (FCM) offers great results in improving the hemoglobin level and further reduces the adverse effects. The FDA clearance of Injectafer in North America, as well as its clearance outside North America under the brand name Ferinject, may be attributed to the substantial increase in the market expansion.

Chronic kidney disease is considered to supplement the growth of the Global Intravenous Iron Drugs Market.

In 2020, the chronic kidney disease sector led the market for intravenous iron medicines, representing 30.8 % of revenue. The rising frequency of CKD and the high incidence of IDA within CKD patients are responsible for its large market share. In individuals with CKD, IDA is a frequent complication. It is uncommon in the early stages of renal sickness, even though it does occur as the disease progresses and kidney function declines. Anemia is caused by a drop in the number of Red Blood Cells (RBCs) in CKD patients. As the number of people with CKD rises, so does the number of those who have Iron Deficiency Anemia (IDA). End-stage renal illness and anemia are linked with each other, dialysis patients with kidney failure and kidney transplant recipients both are at high risk for anemia. In comparison to the general population, CKD patients are more likely to develop anemia (15.4 %) (7.6%). Anemia frequency in CKD patients rose from 8.4% to 53.4 % across stages 1 and 5. Hence, chronic kidney disease patients are likely to boost the market expansion in the forecast period. Global Intravenous Iron Drugs Market 1

Global Intravenous Iron Drugs Market Regional Insights:

North America is projected to dominate the growth of the market with a market share of 39.9% in 2020. Owing to increased approvals and introductions of new intravenous medicine in the US. The rising frequency of cancer, chronic renal disease, and gastrointestinal problems in the region has also contributed to its dominance. In addition, rising awareness of women's health and the growth in the incidence of celiac disease are two more reasons propelling the market growth. The United States and Canada are among the nations included in the area. In 2020, the United States dominated the intravenous iron medication market in the area The Asia Pacific is estimated to adhere to market growth in the forecast timeframe. This may be ascribed to significant players' geographic growth in Asia Pacific nations, as well as the development of healthcare infrastructure and government efforts. Furthermore, the increased incidence of IDA in rising economies like China and India has aided industry expansion. Global Intravenous Iron Drugs Market 2 The objective of the report is to present a comprehensive analysis of the Global Intravenous Iron Drugs Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Global Intravenous Iron Drugs Market dynamics, structure by analyzing the market segments and project the Global Intravenous Iron Drugs Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Global Intravenous Iron Drugs Market make the report investor’s guide.

Global Intravenous Iron Drugs Market Scope: Inquire before buying

Global Intravenous Iron Drugs Market 3

Global Intravenous Iron Drugs Market, by Region

• North America o US o Canada o Mexico • Europe o U.K o France o Germany o Italy o Spain o Sweden o CIS Countries o Rest of Europe • Asia Pacific o China o India o Japan o South Korea o Australia o ASEAN o Rest of Asia Pacific • The Middle East and Africa o South Africa o GCC Countries o Egypt o Nigeria o Rest of ME&A • South America o Brazil o Argentina o Rest of South America

Global Intravenous Iron Drugs Market Key Player

Vifor Pharma Management Ltd. • AMAG Pharmaceuticals • Daiichi Sankyo Company, Ltd. (American Regent. Inc.) • Sanofi S.A. • Pharmacosmos A/S • Shield Therapeutics Plc • AbbVie Inc. (Allergan Plc) • Allergan, Inc. • Sanofi, • Luitpold Pharmaceuticals, Inc. • Galenica Ltd. • Actavis, Inc., • Fresenius Medical Care AG & Co., • American Regent. Inc

FAQs:

1. What was the market size of global Intravenous Iron Drugs market? Ans: Global Intravenous Iron Drugs market size was valued at 2.4 Billion USD in 2020. 2. Which Product Type segment is expected to dominate the global Intravenous Iron Drugs market during the forecast period? Ans: The Ferric Carboxymaltose (FCM) segment dominated the market for intravenous iron drugs and held the largest revenue share of 46.9% in 2020 and is predicted to hold its dominance during the forecast period due to its increasing application, superior performance, and reduced cost. 3. Which region is expected to dominate the global Intravenous Iron Drugs during the forecast period? Ans: North America dominated the intravenous iron drugs market with a share of 39.96% in 2020. This is attributable to the increasing application of intravenous iron drugs in cancer research, increasing adoption of low-cost & compact intravenous iron drugs in clinical diagnostics, and infrastructural development of research laboratories. 4. What is the key driving factor for the growth of the global Intravenous Iron Drugs market? Ans: Key factors that are driving the market growth include the growing prevalence of chronic kidney disease, the increasing number of patients undergoing dialysis, and the rising geriatric population.
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Intravenous Iron Drugs Market Size, by Market Value (US$ Bn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2020 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Intravenous Iron Drugs Market 3.4. Geographical Snapshot of the Intravenous Iron Drugs Market, By Manufacturer share 4. Global Intravenous Iron Drugs Market Overview, 2021-2027 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porter Five Forces Analysis 4.1.6.1. The threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. The threat of Substitute Grades 4.1.6.5. The intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Global Intravenous Iron Drugs Market 5. Supply Side and Demand Side Indicators 6. Global Intravenous Iron Drugs Market Analysis and Forecast, 2021-2027 6.1. Global Intravenous Iron Drugs Market Size & Y-o-Y Growth Analysis. 7. Global Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 7.1. Market Size (Value) Estimates & Forecast By Specimen, 2021-2027 7.1.1. Iron Dextran 7.1.2. Iron Sucrose 7.1.3. Ferric Carboxymaltose 7.1.4. Others 7.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 7.2.1. Chronic Kidney Disease 7.2.2. Inflammatory Bowel Disease 7.2.3. Cancer 7.2.4. Others 8. Global Intravenous Iron Drugs Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2021-2027 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 9.1. Market Size (Value) Estimates & Forecast By Specimen, 2021-2027 9.1.1. Iron Dextran 9.1.2. Iron Sucrose 9.1.3. Ferric Carboxymaltose 9.1.4. Others 9.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 9.2.1. Chronic Kidney Disease 9.2.2. Inflammatory Bowel Disease 9.2.3. Cancer 9.2.4. Others 10. North America Intravenous Iron Drugs Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2021-2027 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 11.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 11.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 12. Canada Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 12.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 12.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 13. Mexico Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 13.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 13.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 14. Europe Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 14.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 14.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 15. Europe Intravenous Iron Drugs Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2021-2027 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 16.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 16.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 17. France Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 17.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 17.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 18. Germany Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 18.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 18.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 19. Italy Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 19.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 19.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 20. Spain Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 20.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 20.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 21. Sweden Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 21.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 21.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 22. CIS Countries Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 22.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 22.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 23. Rest of Europe Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 23.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 23.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 24. Asia Pacific Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 24.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 24.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 25. Asia Pacific Intravenous Iron Drugs Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2021-2027 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 26.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 26.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 27. India Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 27.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 27.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 28. Japan Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 28.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 28.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 29. South Korea Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 29.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 29.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 30. Australia Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 30.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 30.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 31. ASEAN Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 31.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 31.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 32. Rest of Asia Pacific Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 32.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 32.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 33. Middle East Africa Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 33.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 33.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 34. Middle East Africa Intravenous Iron Drugs Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2021-2027 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 35.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 35.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 36. GCC Countries Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 36.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 36.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 37. Egypt Textile Reinforced Concrete e-Market Analysis and Forecasts, 2021-2027 37.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 37.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 38. Nigeria Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 38.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 38.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 39. Rest of ME&A Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 39.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 39.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 40. South America Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 40.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 40.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 41. South America Intravenous Iron Drugs Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2021-2027 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 42.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 42.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 43. Argentina Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 43.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 43.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 44. Rest of South America Intravenous Iron Drugs Market Analysis and Forecasts, 2021-2027 44.1. Market Size (Value) Estimates & Forecast By Product Type, 2021-2027 44.2. Market Size (Value) Estimates & Forecast By Applications, 2021-2027 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Global Intravenous Iron Drugs Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Fiber Grades, and R&D Investment 45.2.2. New Grade Launches and Grade Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment, and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures, and Strategic Alliances/ Sales Agreements 45.3. Company Profile: Key Players 45.3.1. Avomeen 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Grade Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Development 45.3.2. Vifor Pharma Management Ltd. 45.3.3. AMAG Pharmaceuticals 45.3.4. Daiichi Sankyo Company, Ltd. (American Regent. Inc.) 45.3.5. Sanofi S.A. 45.3.6. Pharmacosmos A/S 45.3.7. Shield Therapeutics Plc 45.3.8. AbbVie Inc. 45.3.9. Allergan, Inc. 45.3.10. Sanofi, 45.3.11. Luitpold Pharmaceuticals, Inc. 45.3.12. Galenica Ltd. 45.3.13. Actavis, Inc., 45.3.14. Fresenius Medical Care AG & Co., 45.3.15. American Regent. Inc 46. Primary Key Insights

About This Report

Report ID 119542
Category Healthcare
Published Date Sept 2021
Updated Date
Contact Us